FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313431331> ?p ?o ?g. }

• W4313431331 abstract "To investigate whether self-reported EQ-5D full health state (FHS) after therapeutic intervention for active systemic lupus erythematosus (SLE) is associated with a reduced risk to accrue organ damage. In a separate analysis, we sought to investigate associations between experience of no problems in each one of the five dimensions of EQ-5D and the risk to accrue damage.Data from the open-label extension periods of the BLISS-52 and BLISS-76 trials of belimumab in SLE (NCT00724867; NCT00712933) were used (N = 973). FHS was defined as an experience of no problems in all five EQ-5D dimensions. Organ damage was assessed annually using the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI). Associations between the three-level version of the EQ-5D (EQ-5D-3L) responses at open-label baseline and the first documented increase in organ damage were investigated using Cox regression accounting for age, sex, ancestry, SDI at baseline, and background therapy, and associations with SDI items were investigated using phi (φ) correlation analyses.A total of 147 patients (15.1%) accrued organ damage during follow-up, with the first increase in their SDI score occurring after a mean time of 29.1 ± 19.6 months. Lower proportions of FHS respondents accrued damage over a course of up to 7.9 years of open-label follow-up compared with no FHS respondents (p = 0.004; derived from the logrank test). FHS was associated with a reduced hazard to accrue subsequent organ damage (HR: 0.60; 95% CI: 0.38-0.96; p = 0.033) after adjustments, as was experience of no problems in mobility (HR: 0.61; 95% CI: 0.43-0.87; p = 0.006). No problems in mobility was negatively correlated with musculoskeletal damage accrual (φ = -0.08; p = 0.008) and associated with a lower hazard to accrue musculoskeletal damage in Cox regression analysis (HR: 0.38; 95% CI: 0.19-0.76; p = 0.006).Experience of EQ-5D-3L FHS and no problems in mobility after therapeutic intervention heralded reduced hazard to accrue subsequent organ damage, especially musculoskeletal damage, suggesting that optimisation of these health-related quality of life aspects constitutes a clinically relevant treatment target in patients with SLE, along with clinical and laboratory parameters." @default.
• W4313431331 created "2023-01-06" @default.
• W4313431331 creator A5002838445 @default.
• W4313431331 creator A5004616702 @default.
• W4313431331 creator A5006834335 @default.
• W4313431331 creator A5010406225 @default.
• W4313431331 creator A5036063848 @default.
• W4313431331 creator A5052327641 @default.
• W4313431331 creator A5055660036 @default.
• W4313431331 creator A5059049923 @default.
• W4313431331 creator A5066450516 @default.
• W4313431331 creator A5072460036 @default.
• W4313431331 creator A5086543859 @default.
• W4313431331 date "2022-12-20" @default.
• W4313431331 modified "2023-10-11" @default.
• W4313431331 title "EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus" @default.
• W4313431331 cites W2001882240 @default.
• W4313431331 cites W2051997500 @default.
• W4313431331 cites W2070527591 @default.
• W4313431331 cites W2101274089 @default.
• W4313431331 cites W2103757094 @default.
• W4313431331 cites W2108905161 @default.
• W4313431331 cites W2110177517 @default.
• W4313431331 cites W2116749206 @default.
• W4313431331 cites W2123646230 @default.
• W4313431331 cites W2131457901 @default.
• W4313431331 cites W2136149088 @default.
• W4313431331 cites W2137364521 @default.
• W4313431331 cites W2137638342 @default.
• W4313431331 cites W2141455950 @default.
• W4313431331 cites W2142290318 @default.
• W4313431331 cites W2199189793 @default.
• W4313431331 cites W2293266723 @default.
• W4313431331 cites W2320523466 @default.
• W4313431331 cites W2473786944 @default.
• W4313431331 cites W2486559230 @default.
• W4313431331 cites W2549269809 @default.
• W4313431331 cites W2740944666 @default.
• W4313431331 cites W2791189929 @default.
• W4313431331 cites W2884398163 @default.
• W4313431331 cites W2888359849 @default.
• W4313431331 cites W2901509748 @default.
• W4313431331 cites W2903543521 @default.
• W4313431331 cites W2961892461 @default.
• W4313431331 cites W2971494308 @default.
• W4313431331 cites W3034746363 @default.
• W4313431331 cites W3093343143 @default.
• W4313431331 cites W3093990449 @default.
• W4313431331 cites W3111420086 @default.
• W4313431331 cites W3122703422 @default.
• W4313431331 cites W3155171837 @default.
• W4313431331 cites W3195142473 @default.
• W4313431331 cites W3199011561 @default.
• W4313431331 cites W3215126343 @default.
• W4313431331 cites W4205119248 @default.
• W4313431331 cites W4220656946 @default.
• W4313431331 doi "https://doi.org/10.3389/fmed.2022.1092325" @default.
• W4313431331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36606059" @default.
• W4313431331 hasPublicationYear "2022" @default.
• W4313431331 type Work @default.
• W4313431331 citedByCount "1" @default.
• W4313431331 countsByYear W43134313312023 @default.
• W4313431331 crossrefType "journal-article" @default.
• W4313431331 hasAuthorship W4313431331A5002838445 @default.
• W4313431331 hasAuthorship W4313431331A5004616702 @default.
• W4313431331 hasAuthorship W4313431331A5006834335 @default.
• W4313431331 hasAuthorship W4313431331A5010406225 @default.
• W4313431331 hasAuthorship W4313431331A5036063848 @default.
• W4313431331 hasAuthorship W4313431331A5052327641 @default.
• W4313431331 hasAuthorship W4313431331A5055660036 @default.
• W4313431331 hasAuthorship W4313431331A5059049923 @default.
• W4313431331 hasAuthorship W4313431331A5066450516 @default.
• W4313431331 hasAuthorship W4313431331A5072460036 @default.
• W4313431331 hasAuthorship W4313431331A5086543859 @default.
• W4313431331 hasBestOaLocation W43134313311 @default.
• W4313431331 hasConcept C126322002 @default.
• W4313431331 hasConcept C144024400 @default.
• W4313431331 hasConcept C149923435 @default.
• W4313431331 hasConcept C159654299 @default.
• W4313431331 hasConcept C198451711 @default.
• W4313431331 hasConcept C203014093 @default.
• W4313431331 hasConcept C207103383 @default.
• W4313431331 hasConcept C2775915377 @default.
• W4313431331 hasConcept C2776912625 @default.
• W4313431331 hasConcept C2779134260 @default.
• W4313431331 hasConcept C44249647 @default.
• W4313431331 hasConcept C50382708 @default.
• W4313431331 hasConcept C71924100 @default.
• W4313431331 hasConceptScore W4313431331C126322002 @default.
• W4313431331 hasConceptScore W4313431331C144024400 @default.
• W4313431331 hasConceptScore W4313431331C149923435 @default.
• W4313431331 hasConceptScore W4313431331C159654299 @default.
• W4313431331 hasConceptScore W4313431331C198451711 @default.
• W4313431331 hasConceptScore W4313431331C203014093 @default.
• W4313431331 hasConceptScore W4313431331C207103383 @default.
• W4313431331 hasConceptScore W4313431331C2775915377 @default.
• W4313431331 hasConceptScore W4313431331C2776912625 @default.
• W4313431331 hasConceptScore W4313431331C2779134260 @default.
• W4313431331 hasConceptScore W4313431331C44249647 @default.
• W4313431331 hasConceptScore W4313431331C50382708 @default.

• next